CALICI, a U.S.-based AI-driven drug discovery company, has entered into a strategic partnership with DTCRO, a leading Korean full-service Contract Research Organization (CRO), to collaborate on drug development and ICT-converged platform technologies.

The agreement was established following meetings held during BIO USA 2023 and BIO EUROPE 2023. Through this partnership, CALICI aims to expand the application of its proprietary AI platform in drug discovery while strengthening collaboration with industry partners across the global biopharmaceutical sector.

Founded in 2018, CALICI operates Pharmaco-Net, a web-based cloud platform that leverages artificial intelligence to analyze protein structures, identify promising small-molecule compounds, and accelerate the early stages of drug discovery. By combining CALICI’s AI capabilities with DTCRO’s extensive non-clinical and clinical research expertise, the partnership is expected to drive more efficient and innovative drug development.